Ultragenyx Reports Of Approval Of Evkeeza (evinacumab) In Canada; To Be Commercially Available In Canada Effective Nov. 25
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical Inc. has received approval from Health Canada for its drug Evkeeza (evinacumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies. The drug, intended for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH), will be commercially available in Canada from November 25.
September 25, 2023 | 9:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ultragenyx's approval for Evkeeza in Canada could potentially boost its revenues and market presence in the region.
The approval of Evkeeza by Health Canada is a significant milestone for Ultragenyx, as it allows the company to expand its market presence in Canada. This could potentially lead to increased revenues for the company, hence the positive impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100